- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06781567
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma (HG146)
A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma.
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Jie Shen
- 전화번호: 8211 8268-85197385
- 이메일: jie.shen@hitgen.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200000
- 모병
- Shanghai Oriental Hospital
-
연락하다:
- Ye Guo
- 전화번호: 8268-85197385
- 이메일: pattrickguo@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent form (ICF) and able to comply with study.
- Age ≥18 years, gender unlimited.
- Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
- Estimated survival >12 weeks, as determined by the investigator.
- The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
- Has adequate organ function.
- At least 1 measurable tumor lesion according to RECISTv1.1 criteria.
Exclusion Criteria:
- Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
- Received prior therapies targeting HDAC.
- Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment [small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug.
- Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
- Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
- Prior allogeneic bone marrow transplantation or other solid organ transplantation
- Active infection requiring systemic treatment.
- Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there is no evidence of recurrence and metastasis in the last 5 years.
- A person is known to be allergic to any active ingredient or excipient of the investigational drug.
- Pregnant or lactating women.
- patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Clinical Trial of HG146 Administered to participants with Adenoid cystic carcinoma
Experimental: HG146 Monotherapy Arm Description: Participants will receive HG146 per os at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. |
HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
objective response rate (ORR)
기간: From enrollment to the end of treatment at 4 weeks
|
ORR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
6 Months Progression-Free Survival (PFS)
기간: From enrollment to treatment at 6 months.
|
PFS will be assessed by the investigators using RECIST v. 1.1 |
From enrollment to treatment at 6 months.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: From enrollment to treatment at 12 months
|
PFS will be assessed by the investigators using RECIST v1.1 |
From enrollment to treatment at 12 months
|
|
Duration of response (DoR)
기간: From enrollment to the end of treatment at 4 weeks
|
DOR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Disease control rate (DCR)
기간: From enrollment to the end of treatment at 4 weeks
|
DCR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Overall survival (OS)
기간: From enrollment to the end of treatment at 4 weeks
|
OS will be assessed by the investigators |
From enrollment to the end of treatment at 4 weeks
|
|
Time-to-response (TTR)
기간: From enrollment to the end of treatment at 4 weeks
|
TTR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Population pharmacokinetics (PopPK)
기간: From Cycle1 Day7 to Day13, 21 days per cycle
|
PopPK will be detected to predict exposure level of HG146 in human body. |
From Cycle1 Day7 to Day13, 21 days per cycle
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Ye Guo, Shanghai Oriental Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- HG146CN201
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .